Who Should Be Treated for Helicobacter pylori Infection? A Review of Consensus Conferences and Guidelines
Identifieur interne : 001D52 ( Main/Merge ); précédent : 001D51; suivant : 001D53Who Should Be Treated for Helicobacter pylori Infection? A Review of Consensus Conferences and Guidelines
Auteurs : John Lee [Irlande (pays)] ; Colm O'Morain [Irlande (pays)]Source :
- Gastroenterology [ 0016-5085 ] ; 1997.
English descriptors
Abstract
The publication of the National Institutes of Health Consensus Development Conference guidelines on management of Helicobacter pylori infection in 1994 set a precedence. At present, at least eight European countries have produced national guidelines, and, more recently, the European Helicobacter pylori Study Group also outlined guidelines based on the strength of available evidence. It is generally agreed that H. pylori should be eradicated in peptic ulcer disease. In nonsteroidal anti-inflammatory drug (NSAID)-related ulcers, most countries that considered the issue suggested discontinuing NSAIDs when possible and eradicating H. pylori. The prophylactic eradication of H. pylori was not recommended. A number of panels felt that there was not enough evidence available to recommend eradication of H. pylori in functional dyspepsia, whereas other groups felt that nonulcer dyspepsia, particularly after investigation and with severe or recurrent symptoms, was an indication for eradication therapy. Other conditions (i.e., gastroesophageal reflux disease [GERD] and mucosa-associated lymphoid tissue [MALT] lymphoma) have emerged in this short time as possible indications for H. pylori eradication. There is no evidence that H. pylori infection has a role in the pathogenesis of GERD, but there is evidence suggesting that patients with H. pylori infection who require long-term acid suppression may be at risk of developing atrophic gastritis. The European Helicobacter pylori Study Group has suggested that eradication therapy should be offered to infected family members of patients with gastric cancer. It also recommended that eradication therapy was “strongly recommended” on the basis of “supportive” evidence in gastritis with severe abnormalities and after early resection of early gastric cancer. An “uncertain” recommendation with “equivocal” evidence was given for asymptomatic subjects, extra-alimentary tract disease, the prevention of gastric cancer in the absence of risk factors, and in pediatric patients with recurrent abdominal pain. Despite considerable advances, further research studies are needed to provide definite direction for the treatment of many conditions.
Url:
DOI: 10.1016/S0016-5085(97)80021-2
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001789
- to stream Istex, to step Curation: 001704
- to stream Istex, to step Checkpoint: 001701
Links to Exploration step
ISTEX:D865AFFFA627B6B1CA4461CB73225A3178FAB2AFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Who Should Be Treated for Helicobacter pylori Infection? A Review of Consensus Conferences and Guidelines</title>
<author><name sortKey="Lee, John" sort="Lee, John" uniqKey="Lee J" first="John" last="Lee">John Lee</name>
</author>
<author><name sortKey="O Morain, Colm" sort="O Morain, Colm" uniqKey="O Morain C" first="Colm" last="O'Morain">Colm O'Morain</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D865AFFFA627B6B1CA4461CB73225A3178FAB2AF</idno>
<date when="1997" year="1997">1997</date>
<idno type="doi">10.1016/S0016-5085(97)80021-2</idno>
<idno type="url">https://api.istex.fr/document/D865AFFFA627B6B1CA4461CB73225A3178FAB2AF/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001789</idno>
<idno type="wicri:Area/Istex/Curation">001704</idno>
<idno type="wicri:Area/Istex/Checkpoint">001701</idno>
<idno type="wicri:doubleKey">0016-5085:1997:Lee J:who:should:be</idno>
<idno type="wicri:Area/Main/Merge">001D52</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Who Should Be Treated for Helicobacter pylori Infection? A Review of Consensus Conferences and Guidelines</title>
<author><name sortKey="Lee, John" sort="Lee, John" uniqKey="Lee J" first="John" last="Lee">John Lee</name>
<affiliation wicri:level="1"><country xml:lang="fr">Irlande (pays)</country>
<wicri:regionArea>Department of Gastroenterology, Meath/Adelaide Hospitals, Trinity College, Dublin</wicri:regionArea>
<wicri:noRegion>Dublin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="O Morain, Colm" sort="O Morain, Colm" uniqKey="O Morain C" first="Colm" last="O'Morain">Colm O'Morain</name>
<affiliation wicri:level="1"><country xml:lang="fr">Irlande (pays)</country>
<wicri:regionArea>Department of Gastroenterology, Meath/Adelaide Hospitals, Trinity College, Dublin</wicri:regionArea>
<wicri:noRegion>Dublin</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Irlande (pays)</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Gastroenterology</title>
<title level="j" type="abbrev">YGAST</title>
<idno type="ISSN">0016-5085</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1997">1997</date>
<biblScope unit="volume">113</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="supplement">S</biblScope>
<biblScope unit="page" from="S99">S99</biblScope>
<biblScope unit="page" to="S106">S106</biblScope>
</imprint>
<idno type="ISSN">0016-5085</idno>
</series>
<idno type="istex">D865AFFFA627B6B1CA4461CB73225A3178FAB2AF</idno>
<idno type="DOI">10.1016/S0016-5085(97)80021-2</idno>
<idno type="PII">S0016-5085(97)80021-2</idno>
<idno type="ArticleID">80021</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0016-5085</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>EHPSG</term>
<term>GERD</term>
<term>MALT</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">The publication of the National Institutes of Health Consensus Development Conference guidelines on management of Helicobacter pylori infection in 1994 set a precedence. At present, at least eight European countries have produced national guidelines, and, more recently, the European Helicobacter pylori Study Group also outlined guidelines based on the strength of available evidence. It is generally agreed that H. pylori should be eradicated in peptic ulcer disease. In nonsteroidal anti-inflammatory drug (NSAID)-related ulcers, most countries that considered the issue suggested discontinuing NSAIDs when possible and eradicating H. pylori. The prophylactic eradication of H. pylori was not recommended. A number of panels felt that there was not enough evidence available to recommend eradication of H. pylori in functional dyspepsia, whereas other groups felt that nonulcer dyspepsia, particularly after investigation and with severe or recurrent symptoms, was an indication for eradication therapy. Other conditions (i.e., gastroesophageal reflux disease [GERD] and mucosa-associated lymphoid tissue [MALT] lymphoma) have emerged in this short time as possible indications for H. pylori eradication. There is no evidence that H. pylori infection has a role in the pathogenesis of GERD, but there is evidence suggesting that patients with H. pylori infection who require long-term acid suppression may be at risk of developing atrophic gastritis. The European Helicobacter pylori Study Group has suggested that eradication therapy should be offered to infected family members of patients with gastric cancer. It also recommended that eradication therapy was “strongly recommended” on the basis of “supportive” evidence in gastritis with severe abnormalities and after early resection of early gastric cancer. An “uncertain” recommendation with “equivocal” evidence was given for asymptomatic subjects, extra-alimentary tract disease, the prevention of gastric cancer in the absence of risk factors, and in pediatric patients with recurrent abdominal pain. Despite considerable advances, further research studies are needed to provide definite direction for the treatment of many conditions.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001D52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Belgique |area= OpenAccessBelV2 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:D865AFFFA627B6B1CA4461CB73225A3178FAB2AF |texte= Who Should Be Treated for Helicobacter pylori Infection? A Review of Consensus Conferences and Guidelines }}
![]() | This area was generated with Dilib version V0.6.25. | ![]() |